logo

Synlogic Inc (SYBX)



Trade SYBX now with
  Date
  Headline
9/4/2019 6:05:11 AM Synlogic Presents Full Clinical Data Set From Phase 1/2a Study Of SYNB1618
8/20/2019 6:06:49 AM Synlogic Discontinues Development Of SYNB1020 To Treat Hyperammonemia
8/9/2019 9:17:53 AM Wedbush Is Increasing Synlogic Inc (SYBX) FY20 Estimate To -1.73 From -1.86
8/9/2019 9:17:35 AM Wedbush Is Raising Synlogic Inc (SYBX) Q4 20 Estimate To -0.40 From -0.43
8/9/2019 9:17:17 AM Wedbush Is Increasing Synlogic Inc (SYBX) Q3 20 Estimate To -0.41 From -0.44
8/9/2019 9:17:04 AM Wedbush Is Increasing Synlogic Inc (SYBX) Q2 20 Estimate To -0.47 From -0.51
8/9/2019 9:16:50 AM Wedbush Is Increasing Synlogic Inc (SYBX) Q1 20 Estimate To -0.45 From -0.49
8/9/2019 9:16:36 AM Wedbush Is Increasing Synlogic Inc (SYBX) FY19 Estimate To -1.75 From -1.87
8/9/2019 9:02:55 AM Wedbush Is Increasing Synlogic Inc (SYBX) Q4 19 Estimate To -0.39 From -0.43
8/9/2019 9:02:44 AM Wedbush Is Increasing Synlogic Inc (SYBX) Q3 19 Estimate To -0.40 From -0.43
8/9/2019 9:02:09 AM Wedbush Reiterates Synlogic Inc (SYBX) At Outperform With $20 Price Target
7/15/2019 6:04:30 AM Synlogic Reports Positive Top-line Data From Phase 1/2a Study Of SYNB1618
6/12/2019 1:19:52 PM Wedbush Is Increasing Synlogic Inc (SYBX) 2020 Estimate To -1.86 From -1.91
6/12/2019 1:19:37 PM Wedbush Is Increasing Synlogic Inc (SYBX) 4Q20 Estimate To -0.43 From -0.44
6/12/2019 1:19:22 PM Wedbush Is Increasing Synlogic Inc (SYBX) 3Q20 Estimate To -0.44 From -0.45
6/12/2019 1:19:02 PM Wedbush Is Increasing Synlogic Inc (SYBX) 1Q20 Estimate To -0.51 From -0.52
  
 
>